The Cogstate Blog

Expert perspectives on ensuring higher quality cognitive measures

The International Shopping List Test in Alzheimer’s Disease Clinical Trials

October 19, 2017

Objective cognitive impairment typical of Alzheimer’s disease can be established using episodic memory tests, and word list learning tests are a type of episodic memory test commonly used. The Cogstate International Shopping List Test (ISLT) is a word list learning test that has several advantages for sensitively measuring episodic memory in global clinical trials, including […]

Key Takeaways from the 2017 National Alzheimer’s Summit

October 12, 2017

By 2050, more than 13 million Americans are estimated to be living with Alzheimer’s disease, and the costs of care is expected to mount to over a trillion dollars. In this video, Cogstate CEO, Brad O’Connor, discusses key takeaways from his experience presenting at the National Alzheimer’s Summit hosted by UsAgainstAlzheimer’s. He heard perspectives from […]

Subject Eligibility Review and Diagnostic Adjudication

September 22, 2017

When inappropriate subjects are enrolled into a clinical trial, the success of the study can be at risk. Sponsors seek to protect the integrity of their study by identifying subjects who violate the protocol, and preventing them from being inappropriately randomized to treatment. Dr. Edward Bartolic, Senior Scientific Director at Cogstate, gives an overview and […]